Clinical Trials Browser

Recruiting × INDUSTRY × sacituzumab govitecan × Clear all

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03424005 2026-03-16

Morpheus-panBC

Phase 1/2 Recruiting

792 enrolled

Breast

Breast Neoplasms

NCT03547973 2026-03-16

TROPHY U-01

Phase 2 Recruiting

827 enrolled 1 FDA

Genitourinary

Metastatic Urothelial Cancer

NCT04617522 2026-02-11

Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

Phase 1 Recruiting

30 enrolled

Neoplasm Metastasis, Liver Failure

NCT06926920 2026-01-30

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

Phase 1/2 Recruiting

100 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05633654 2026-01-20

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Phase 3 Recruiting

1,514 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05867251 2025-11-19

Study of AVZO-021 in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

430 enrolled

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04794699 2025-11-12

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

Phase 1 Recruiting

180 enrolled

GenitourinaryThoracic

Urinary Bladder Neoplasms, Lung Neoplasms

NCT06827613 2025-09-24

START-002

Phase 1/2 Recruiting

50 enrolled

Breast

Triple Negative Locally Advanced Non-resectable Breast Cancer

NCT06167317 2025-03-12

Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors

Phase 1 Recruiting

254 enrolled

Other solid neoplasm

Advanced Solid Tumors

Clinical Trials

VELOCITY-Lung

Morpheus-panBC

TROPHY U-01

Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Study of AVZO-021 in Patients With Advanced Solid Tumors

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

START-002

Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors